Venom immunotherapy (VIT) is a life-saving medical treatment for individuals allergic to Hymenoptera species. Delivery of VIT is a complex process that requires proper extract preparation, shipping, storage, refrigeration, and administration by qualified medical personnel in a facility that can manage a life-threatening allergic emergency (anaphylaxis). Successful VIT requires 3 to 5 years of uninterrupted maintenance injections, which may be difficult to maintain during deployments, particularly in combat operations. The complexity of VIT has resulted in service members being deemed nondeployable and has led to interruption or discontinuation of VIT for deployed service members in the past. We report the case of a 34-year-old Army National Guard soldier who successfully received maintenance VIT while deployed to Operation Iraqi Freedom. This case demonstrates that, with proper coordination and appropriate risk assessment, continuation of complex medical care, such as VIT, can be supported in a combat zone.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.7205/milmed.172.5.544 | DOI Listing |
Br J Anaesth
March 2025
Department of Surgery, UMons, Research Institute for Health Sciences and Technology, University of Mons, Mons, Belgium; Department of Anesthesiology, Helora, Mons, Belgium. Electronic address:
J Am Coll Cardiol
March 2025
Cedars Sinai Medical Center, Los Angeles, California, USA. Electronic address:
This updated Heart Valve Collaboratory framework addresses the growing concern for transcatheter valve failure (TVF) following transcatheter aortic valve replacement (TAVR). With the increasing volume of redo-TAV and surgical TAV explantation, there is a critical need for standardized pathways and protocols for evaluating TVF using echocardiography and cardiac computed tomography (CT) angiography. This document clarifies prior definitions of bioprosthetic valve deterioration and bioprosthetic valve failure in a practical, imaging directed context for TAVR.
View Article and Find Full Text PDFJ Am Coll Cardiol
March 2025
National Amyloidosis Centre, University College London, Royal Free Hospital, London, United Kingdom.
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed chronic disease associated with progressive heart failure that results in impaired quality of life, repeated hospitalizations, and premature death. Acoramidis is a selective, oral transthyretin stabilizer recently approved by the U.S.
View Article and Find Full Text PDFOccup Environ Med
March 2025
Research Directorate, Veterans Affairs Canada, Charlottetown, Prince Edward Island, Canada
Objectives: To describe rates of overall and type-specific primary cancers in Canadian Armed Forces (CAF) personnel and Veterans with a first enrolment in the CAF between 1976 and 2016, with comparisons to the Canadian general population (CGP).
Methods: This retrospective cohort study linked CAF administrative data to national cancer registries. Primary cancer diagnoses were ascertained from 1976 to 2017.
Background: This study aimed to investigate the assignment of" patient attendants"as outlined in the guidelines for home-based red blood cell transfusion therapy in Japan.
Methods: Among patients with cancer who received home-based treatment at our institution during the study period, 93 patients who underwent home-based red blood cell transfusion therapy and either died or were diagnosed in their terminal stage were included. Data were collected from medical records and analyzed retrospectively.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!